B2M and neoplasm: To establish whether bone resorption is associated with myeloma burden, we examined serum levels of C-terminal telopeptide (CTX), a biochemical marker of bone resorption, and β2-microglobulin (β2m) as a measure of tumour burden in 118 patients with newly diagnosed myeloma.